Infervision Secures China's First NMPA Class III Certification for Pneumonia AI and Lands EU Government Procurement Order Amid IPO Filing

On April 1, 2021, the National Medical Products Administration (NMPA) officially approved Infervision Medical Technology Co., Ltd.’s (hereinafter referred to as “Infervision”) “CT Imaging Auxiliary Triage and Assessment Software for Pneumonia” for Class III medical device certification. This marks not only one of the first Class III AI certifications for pneumonia approved by China’s NMPA, but also the second NMPA Class III certification granted to Infervision within just four months. With this approval, Infervision has now secured market access for its pneumonia-related products in three major markets: the European Union (CE marking), Japan (PMDA approval), and China (NMPA approval).

On the same day, Infervision’s European branch also announced good news: the European Union government decided to centrally procure Infervision’s AI solution for COVID-19 for the second time. During this critical period when the epidemic remains severe in Europe, the EU’s firm decision to purchase an artificial intelligence solution from China is not only an endorsement of Infervision but also a recognition of Chinese technology.

In January 2020, the COVID-19 pandemic suddenly erupted. In the face of the outbreak,Infervision immediately initiated the R&D of AI products targeting the COVID-19 pandemic. Meanwhile, Infervision launched a bidirectional mechanism for joint R&D and clinical validation with hospitals including Tongji Hospital affiliated to Huazhong University of Science and Technology, Zhongnan Hospital of Wuhan University, Shenzhen Third People’s Hospital (National Clinical Research Center for Infectious Diseases), and Beijing Haidian Hospital, upgrading and developing AI solutions for COVID-19 in response to clinical needs.On January 29, the first prototype system was launched at Tongji Hospital in Wuhan. Infervision’s intelligent auxiliary screening and epidemic monitoring system for pneumonia can rapidly assist doctors, hospitals, and government agencies in diagnosing COVID-19, conducting quantitative assessments, and monitoring the epidemic. During the fight against the pandemic, it has made positive contributions in various areas, including epidemic prevention and control and disease diagnosis.

▲ Infervision’s AI Pneumonia Product Launched in Hospitals Across Multiple Countries

▲ Infervision’s European Team Rushes to Aid Italy

Infervision’s AI solution for pneumonia not only plays a vital role on the front lines of epidemic control in China, but has also been deployed in hospitals across Japan, Italy, Germany, and many other countries and regions. It empowers physicians worldwide who are fighting on the front lines against the COVID-19 pandemic, leveraging technology to benefit humanity. Infervision remains committed to this mission, earning consistent acclaim from doctors both domestically and internationally, as well as close attention from media outlets across various sectors.Sun Yipeng, Head of Infervision’s European Division, once recounted his experience traveling to Italy’s epidemic-stricken regions: “When we finally reached the Italian border after overcoming numerous obstacles, Italian soldiers stopped us due to the nationwide lockdown. However, upon presenting our documentation proving our destination was a hospital, they registered our entry while expressing their gratitude, saying, ‘Thank you for helping Italy in its most perilous hour!’” Radiologists at the University Hospital affiliated with Libera Università Medica di Roma also expressed deep appreciation when faced with the Infervision European team who had traveled against the tide to assist them, stating, “We are truly grateful to Chinese institutions and companies for coming to Italy and making such efforts under the current circumstances.”

In the fight against pneumonia, Infervision has consistently adhered to the developmental principles of evidence-based medicine and upheld a rigorous scientific spirit. Through validation in clinical applications and continuous improvement, Infervision drives the advancement and development of medical science.A total of 19 scientific manuscripts have been submitted, with 11 SCI papers published in internationally renowned journals such as JAMA and The Lancet Digital Health, and 4 papers published in domestic core journals such as the Chinese Journal of Radiology.Scientific research in the fight against the epidemic has become a hallmark of national enterprises, earning international acclaim. With a solid foundation in scientific research, the use of AI to enhance diagnostic and treatment outcomes has been further demonstrated, with improvements in the efficiency and quality of diagnostic assessments, quantitative evaluations, and outcome assessments.

Artificial intelligence has demonstrated tremendous power in the fight against the epidemic, further strengthening our original aspiration to promote the building of a community of common health for mankind through technology. In the future, Infervision will continue to focus on the AI healthcare sector, adhere to its “one horizontal, one vertical” product strategy layout, base itself in China while keeping a global perspective, and improve human life and health with AI. With A.I., We Improve Human Life!